To include your compound in the COVID-19 Resource Center, submit it here.

Soaring Kite

Buysiders’ views on Kite’s $12 billion takeout price

Four buysiders told BioCentury that Kite Pharma Inc. (NASDAQ:KITE) may have gotten maximum value for shareholders in its near $12 billion takeout by Gilead Sciences Inc. (NASDAQ:GILD) given the run-up in the stock since the start of the year.

On Aug. 28, Gilead announced it will acquire Kite

Read the full 483 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers